Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV000987728 | SCV001137163 | pathogenic | Retinitis pigmentosa 25 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001062996 | SCV001227824 | pathogenic | not provided | 2024-10-15 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg1374*) in the EYS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EYS are known to be pathogenic (PMID: 18836446, 20333770). This variant is present in population databases (no rsID available, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with retinitis pigmentosa (PMID: 21069908, 29159838, 29550188). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 802236). For these reasons, this variant has been classified as Pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003226411 | SCV003922790 | pathogenic | Retinitis pigmentosa | 2023-03-21 | criteria provided, single submitter | clinical testing | Variant summary: EYS c.4120C>T (p.Arg1374X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 1.3e-05 in 153766 control chromosomes (gnomAD). c.4120C>T has been reported in the literature as a biallelic genotype in individuals affected with Retinitis Pigmentosa (e.g. Barragan_2010, Sengillo_2018). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three ClinVar submitters have assessed the variant since 2014: all three classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Ophthalmic Genetics Group, |
RCV003226411 | SCV004030402 | pathogenic | Retinitis pigmentosa | 2023-07-24 | criteria provided, single submitter | research | Clinical significance based on ACMG v2.0 |
Baylor Genetics | RCV000987728 | SCV004192929 | pathogenic | Retinitis pigmentosa 25 | 2024-03-20 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000987728 | SCV005670609 | pathogenic | Retinitis pigmentosa 25 | 2024-05-17 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001274881 | SCV001459423 | pathogenic | Autosomal recessive retinitis pigmentosa | 2020-09-16 | no assertion criteria provided | clinical testing |